Takeda Head Admits Firm Behind In Replacing Patent-Losing Blockbusters
This article was originally published in PharmAsia News
CEO says the near future for overcoming patent losses of key drugs is not rosy, due in part to a gap between expirations and getting well-selling substitutes to market.
You may also be interested in...
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.
As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.